485 patents
Page 5 of 25
Utility
Nuclear Receptor Modulators
2 Mar 23
Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
Filed: 23 Jul 21
Utility
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
28 Feb 23
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Filed: 7 Jun 22
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
23 Feb 23
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew M. Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
Filed: 23 Sep 22
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
23 Feb 23
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew M. Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
Filed: 23 Sep 22
Utility
ANTI-CCR8 Antibodies
16 Feb 23
The present disclosure provides anti-CCR8 antibodies, including compositions and methods of using such antibodies.
Andrew J. McCluskey, Amanda M. Schmidt Paustian, Jane Seagal, Julie L. Wilsbacher
Filed: 27 Jul 22
Utility
Methods of treating crohn's disease and ulcerative colitis
31 Jan 23
The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor.
Aileen L. Pangan, Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado De Lacerda, Anne M. Robinson, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
Filed: 28 Apr 22
Utility
Automatic injection devices having overmolded gripping surfaces
31 Jan 23
Exemplary embodiments provide automatic injection devices, housing components for automatic injection devices and methods for fabricating the same.
Joseph F. Julian, Chuan Li, Aaron B. Eiger, Mark Kurth, Sabrina Katz, Adam Callif, James C. Stango
Filed: 26 Jan 18
Utility
Methods of Treating Acute Myeloid Leukemia and Managing Cytopenia
26 Jan 23
Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine.
Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
Filed: 15 Sep 22
Utility
Protein Tyrosine Phosphatase Inhibitors and Methods of Use Thereof
19 Jan 23
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Elliot P. Farney, Reza Shiroodi, Zhaoming Xiong, Qingwei Zhang, Matthew J. O'Connor, Geoff T. Halvorsen, Hongyu Zhao, Christina Baumgartner, Jennifer M. Frost, Philip R. Kym, Jason R. Abbott, Andrew Bogdan, Christos Economou, Xueqing Wang
Filed: 16 Jun 22
Utility
Dosing Regimens for Use In Treating Myelofibrosis and Mpn-related Disorders with Navitoclax
19 Jan 23
The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
John Hayslip, Leanne M. Holes, Sven Mensing, Silpa Nuthalapati
Filed: 15 Feb 22
Utility
Protein Formulations and Methods of Making Same
12 Jan 23
The invention provides an aqueous formulation comprising water and a protein, and methods of making the same.
Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
Filed: 25 Jan 22
Utility
Methods of Treating Acute Myeloid Leukemia and Managing Cytopenia
5 Jan 23
Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine.
Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
Filed: 7 Jun 22
Utility
Elagolix sodium compositions and processes
3 Jan 23
The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.
Niharika Chauhan, Raimundo Ho, Albert Kruger, Samrat Mukherjee, Stephen T. Chau, Erika Crane, Alex Fabian, Sanjay Chemburkar, Travis Dunn
Filed: 23 Jul 19
Utility
Prescription drug fulfillment system and method
3 Jan 23
A system for fulfilling a prescription is provided.
Pankaj Dubey, Vaibhav Jindal
Filed: 7 Apr 20
Utility
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof
27 Dec 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Filed: 27 May 22
Utility
Dihydropyrrolopyridine inhibitors of ROR-gamma
27 Dec 22
David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
Filed: 9 Sep 20
Utility
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
27 Dec 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Ahmed A. Othman, Mohamed-Eslam F. Mohamed, Ben Klünder, Aileen L. Pangan
Filed: 27 May 22
Utility
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
27 Dec 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Filed: 27 May 22
Utility
ANTI-DLL4/VEGF Dual Variable Domain Immmunoglobulin and Uses Thereof
22 Dec 22
Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
Filed: 28 Jan 22
Utility
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
13 Dec 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process.
Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Aileen L. Pangan, In-Ho Song
Filed: 11 Apr 22